REVEAL Trial: Difference between revisions
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Timeline== | |||
Start Date: June 2011 <br> | |||
Expected End Date: January 2017 | |||
==Objective== | ==Objective== | ||
Revision as of 03:39, 18 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
REVEAL Trial On the Web |
|
American Roentgen Ray Society Images of REVEAL Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Timeline
Start Date: June 2011
Expected End Date: January 2017
Objective
The Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL) is prospective, randomized, multicenter, placebo-controlled, double-blind clinical trial that will enroll 30,000 patients with high low density lipoprotein (LDL) receiving HMG-CoA reductase inhibitor (statin) therapy.
The study will evaluate the therapeutic effect of anacetrapib 100 mg on lipid profile alteration and role in reduction of cardiovascular morbidity and mortality in patients with baseline circulatory problems.